melanogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
23 November Acoustic Nanoscale Separation via Wave-pillar Excitation Resonance (ANSWER) is demonstrated as a way of separating nanoparticles, especially small extracellular vesicles, from biofluids in under 10 minutes. A study reports phages have a large variety of CRISPR-Cas systems. They possibly may use them to edit hosts' genes and for competitive advantages, e.g. against rival phages. These systems could be useful for CRISPR-Cas gene editing. A study reports estimated contemporary prevalence and associations with belief in witchcraft around the world, which (in their data) varied between 9% and 90% between nations and is still a widespread element in worldviews globally. It also shows associations such as with low "innovative activity", lower life expectancy and high religiosity. Geneticists report that the fastest-evolved regions of the human genome, they call HAQERs, "rapidly diverged in an episodic burst" of positive selection prior to the human-Neanderthal split and identify over 1,500 such HAQERs that substantially distinguish humans from related other apes via datasets such as of HARs and experiments that use embryonic mouse brains.
=== Further clinical studies of radiolabeled somatostatin receptor antagonists === Ga-NODAGA-JR11 had entered further clinical studies as an imaging agent, while Lu-DOTA-JR11 had similar research done as a therapeutic agent, as JR11 has a high binding affinity for ssrt2 subtype receptors which are highly expressed on the surface of tumor cells. Gallium-containing agonists had already been established as an imaging agent. Lutetium-containing agonists were used as a therapeutic agent in peptide receptor radionuclide therapy, due to the lower energy electrons emitted, and γ-emission causing easier dose adjustment to patient characteristics to avoid renal damage. The NODAGA chelator was used over DOTA in Gallium antagonists due to higher binding affinity, while no Lu-NODAGA compounds were developed due to established usage of Lu-DOTA derivative agonist drugs, and poor uptake compared to DOTA, which is reverse that of the gallium-containing antagonists.
The US Air Force had been developing a program to launch the first man in space, named Man in Space Soonest. This program studied several different types of one-man space vehicles, settling on a ballistic re-entry capsule launched on a derivative Atlas missile, and selecting a group of nine candidate pilots. After NASA's creation, the program was transferred over to the civilian agency's Space Task Group and renamed Project Mercury on November 26, 1958. The Mercury spacecraft was designed by the STG's chief engineer Maxime Faget. NASA selected a new group of astronaut (from the Greek for "star sailor") candidates from Navy, Air Force and Marine test pilots, and narrowed this down to a group of seven for the program. Capsule design and astronaut training began immediately, working toward preliminary suborbital flights on the Redstone missile, followed by orbital flights on the Atlas. Each flight series would first start unpiloted, then carry a non-human primate, then finally humans. The Mercury spacecraft's principal designer was Maxime Faget, who started research for human spaceflight during the time of the NACA. It consisted of a conical capsule with a cylindrical pack of three solid-fuel retro-rockets strapped over a beryllium or fiberglass heat shield on the blunt end. Base diameter at the blunt end was 6.0 feet (1.8 m) and length was 10.8 feet (3.3 m); with the launch escape system added, the overall length was 25.9 feet (7.9 m). With 100 cubic feet (2.8 m3) of habitable volume, the capsule was just large enough for a single astronaut.
Alkali metal cations do not usually form coordination complexes with simple Lewis bases due to their low charge of just +1 and their relatively large size; thus the Li+ ion forms most complexes and the heavier alkali metal ions form less and less (though exceptions occur for weak complexes). Lithium in particular has a very rich coordination chemistry in which it exhibits coordination numbers from 1 to 12, although octahedral hexacoordination is its preferred mode. In aqueous solution, the alkali metal ions exist as octahedral hexahydrate complexes [M(H2O)6]+, with the exception of the lithium ion, which due to its small size forms tetrahedral tetrahydrate complexes [Li(H2O)4]+; the alkali metals form these complexes because their ions are attracted by electrostatic forces of attraction to the polar water molecules. Because of this, anhydrous salts containing alkali metal cations are often used as desiccants. Alkali metals also readily form complexes with crown ethers (e.g. 12-crown-4 for Li+, 15-crown-5 for Na+, 18-crown-6 for K+, and 21-crown-7 for Rb+) and cryptands due to electrostatic attraction.
Sources: en.wikipedia.org
In Latin America, money laundering is mainly linked to drug trafficking activities and to having connections with criminal activity, such as crimes that have to do with arms trafficking, human trafficking, extortion, blackmail, smuggling, and acts of corruption of people linked to governments, such as bribery, which are more common in Latin American countries. There is a relationship between corruption and money laundering in developing countries. The economic power of Latin America increases rapidly and without support, these fortunes being of illicit origin having the appearance of legally acquired profits. With regard to money laundering, the ultimate goal of the process is to integrate illicit capital into the general economy and transform it into licit goods and services. The money laundering practice uses various channels to legalize everything achieved through illegal practices. As such, it has different techniques depending on the country where this illegal operation is going to be carried out:
== Particular oligomeric prodelphinidins == Prodelphinidin B3 (gallocatechin-(4α→8)-catechin) and prodelphinidin B9 (epigallocatechin-(4α→8)-catechin) can be isolated in beer. Prodelphinidin C2 (gallocatechin-(4α→8)-gallocatechin-(4α→8)-catechin) can be isolated in malt. The A-type proanthocyanidin epigallocatechin-(2β→7,4β→8)-epicatechin can be found in the leaves of Dioclea lasiophylla,
C-value The total amount of DNA contained within a haploid nucleus (e.g. a gamete) of a particular organism or species, expressed in number of base pairs or in units of mass (typically picograms); or, equivalently, one-half the amount in a diploid somatic cell. For simple diploid eukaryotes the term is often used interchangeably with genome size, but in certain cases, e.g. in hybrid polyploids descended from parents of different species, the C-value may actually represent two or more distinct genomes contained within the same nucleus. C-values apply only to genomic DNA, and notably exclude extranuclear DNA.
Caution is advised for the use of morphine during pregnancy or breastfeeding, as it may affect the health of the baby. Morphine was first isolated in 1804 by German pharmacist Friedrich Sertürner. This is believed to be the first isolation of a medicinal alkaloid from a plant. Merck began marketing it commercially in 1827. Morphine was more widely used after the invention of the hypodermic syringe in 1853–1855. Sertürner originally named the substance morphium, after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. The primary source of morphine is isolation from poppy straw of the opium poppy. In 2013, approximately 523 tons of morphine were produced. Approximately 45 tons were used directly for pain, an increase of 400% over the last twenty years. Most use for this purpose was in the developed world. About 70% of morphine is used to make other opioids such as hydromorphone, oxymorphone, and heroin. It is a Schedule II drug in the United States, Class A in the United Kingdom, and Schedule I in Canada. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 156th most commonly prescribed medication in the United States, with more than 3 million prescriptions. It is available as a generic medication.
=== Role in the dental team === Denturists are an important part of the dental team. They often work alongside general dentists, dental specialists and other members of a dental team in both private and public sectors of the oral health workforce. They can also work independently in their own clinic with patients providing appropriate management and treatment of dentures and other oral appliances. Denturists are well educated in clinical and technical knowledge of denture care, as well as completing many hours of practical skills in producing dentures. They ultimately receive more comprehensive study in oral prosthetics than any other health professional including the general dentist since dental schools less emphasis in their curriculum about removable prosthetics and focus on implantology in contrast denturist schools teaches mainstream of removable prosthetics and dentures and spend several years for training. Therefore, the collaborative role of denturists provides an important model of re-allocating dental services to alleviate stresses from the general dentists, reserving time for restorative, cosmetic, hygiene, and emergency dental procedures. Denturists differ from both dental technicians and prosthodontists. Dental technicians are registered members of the dental team who support dental practitioners in the delivery of dental services. Prosthodontists are qualified dentists, who have specialized in making fixed or removable appliances for patients.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.